Abstract
Thanks to the most recent technological innovations, the ability of grayscale ultrasound (US) in the detection of focal liver lesions (FLLs) has significantly improved, even if small or deeply located. However, the characterization remains a challenge even for experienced sonographers except for hemangiomas with typical US appearance detected in patients with no history of malignancy or chronic liver disease [1].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bartolotta TV, Taibbi A, Midiri M, Matranga D, Solbiati L, Lagalla R (2011) Indeterminate focal liver lesions incidentally discovered at gray-scale US: role of contrast-enhanced sonography. Invest Radiol 46(2):106–115
Malhi H, Grant EG, Duddalwar V (2014) Contrast-enhanced ultrasound of the liver and kidney. Radiol Clin North Am 52(6):1177–1190
Cantisani V, Grazhdani H, Fioravanti C, Rosignuolo M, Calliada F, Messineo D, Bernieri MG, Redler A, Catalano C, D’Ambrosio F (2014) Liver metastases: contrast-enhanced ultrasound compared with computed tomography and magnetic resonance. World J Gastroenterol 20(29):9998–10007
Bartolotta TV, Taibbi A, Midiri M, De Maria M (2008) Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound. Abdom Imaging 33(5):501–511
Bartolotta TV, Taibbi A, Matranga D, Midiri M, Lagalla R (2015) 3D versus 2D contrast-enhanced sonography in the evaluation of therapeutic response of hepatocellular carcinoma after locoregional therapies: preliminary findings. Radiol Med [Epub ahead of print]
Burns PN, Wilson SR (2007) Focal liver masses: enhancement patterns on contrast-enhanced images—concordance of US scans with CT scans and MR images. Radiology 242:162–174
Piscaglia F, Bolondi L, Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents (2006) The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 32(9):1369–1375
Skyba DM, Price RJ, Linka AZ, Skalak TC, Kaul S (1998) Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. Circulation 98(4):290–293
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen M-H, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen ELS, Mattrey RF, Moriyasu F, Solbiati L, Weskott H-P, Xu H-X (2013) Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver – update 2012. A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 39(2):187–210
Main ML, Goldman JH, Grayburn PA (2009) Ultrasound contrast agents: balancing safety versus efficacy. Expert Opin Drug Saf 8:49–56
Main ML, Ryan AC, Davis TE et al (2008) Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol 102:1742–1746
Coleman JL, Navid F, Furman WL, McCarville MB (2014) Safety of ultrasound contrast agents in the pediatric oncologic population: a single-institution experience. AJR Am J Roentgenol 202(5):966–970
Schreiber-Dietrich DG, Cui XW, Piscaglia F, Gilja OH, Dietrich CF (2014) Contrast enhanced ultrasound in pediatric patients: a real challenge. Z Gastroenterol 52(10):1178–1184
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Bartolotta, T.V., Taibbi, A., Midiri, M. (2015). Introduction. In: Atlas of Contrast-enhanced Sonography of Focal Liver Lesions. Springer, Cham. https://doi.org/10.1007/978-3-319-17539-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-17539-3_1
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-17538-6
Online ISBN: 978-3-319-17539-3
eBook Packages: MedicineMedicine (R0)